FindTrial
Sign In

Study for optimization of treatment regimen Cryptococcal meningitis during induction period

Study for optimization of treatment regimen Cryptococcal meningitis during induction period

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900023395
Enrollment
Unknown
Registered
2019-05-25
Start date
2019-06-15
Completion date
Unknown
Last updated
2019-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cryptococcal meningitis

Interventions

Experimental group:Voriconazole+5-FC
Control group:Amphotericin B+5-FC

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with cryptococcal meningitis with the diagnostic standard of cryptococcal meningitis in the Expert Consensus on the Diagnosis and Treatment of Cryptococcal Meningitis of 2018, aged over 18 years.

Exclusion criteria

Exclusion criteria: 1. Patients with tuberculous meningitis; 2. patients with abnormal liver and kidney function.

Design outcomes

Primary

MeasureTime frame
Determination of voriconazole in the plasma;Determination of voriconazole in the cerebrospinal fluid;cerebrospinal pressure;Biochemistry of cerebrospinal fluid;cerebrospinal fluid routine;Cerebrospinal fluid smear;—

Countries

China

Contacts

Public ContactXiaoju Lv

West China Hospital, Sichuan University

lvxj3369@163.com+86 18980601315

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026